| Budget Amount *help |
¥3,770,000 (Direct Cost: ¥2,900,000、Indirect Cost: ¥870,000)
Fiscal Year 2015: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2014: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Outline of Final Research Achievements |
In this study, we determined that MIA facilitates STOX2 expression.In vitro analysis using OSCC cells revealed that MIA siRNA decreased expression of STOX2. Moreover, STOX2 accelerated OSCC cell growth, invasion, suppressed apoptosis, and enhanced resistance to paclitaxel, cisplatin, and 5-FU.MIA and STOX2 mRNA levels were higher in OSCCs than in normal oral epithelial cells, and upregulation of STOX2 was significantly correlated with overexpression of MIA. In 202 OSCC specimens, immunostaining for STOX2 was associated with nodal metastasis and MIA expression. Furthermore, MIA expression and STOX2 expression were associated with poor outcome in OSCCs. Our results suggest that MIA-STOX2 signaling may be a useful diagnostic and therapeutic target in OSCCs.
|
